Cartilage oligomeric matrix protein: a new promising biomarker of liver fibrosis in chronic hepatitis C

Infect Dis (Lond). 2015;47(12):915-8. doi: 10.3109/23744235.2015.1075659. Epub 2015 Aug 12.

Abstract

Cartilage oligomeric matrix protein (COMP) is a biomarker of fibrosis in lung and skin. In this exploratory study we investigated the biomarker potential of COMP in chronic hepatitis C (CHC). We included consecutive patients with CHC admitted to the Department of Infectious Diseases, Lund University Hospital. COMP was analysed in serum using ELISA. The correlations between COMP and liver fibrosis, determined by transient elastography (TE) (n = 47) and liver biopsy (n = 28) were assessed. We also studied COMP prospectively in relation to antiviral treatment (n = 10). COMP correlated with the degree of liver fibrosis as assessed by TE (r = 0.71, p < 0.001) and liver biopsy (rs = 0.65, p < 0.001). After successful treatment of CHC, COMP decreased from 18 to 13 U/l (p = 0.011). We suggest that COMP is associated with the stage of liver fibrosis in CHC. The biomarker potential of COMP in CHC warrants further investigation.

Keywords: COMP; biomarker; chronic hepatitis C; liver fibrosis; transient elastography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Biomarkers / blood*
  • Biopsy
  • Cartilage Oligomeric Matrix Protein / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Liver Cirrhosis / diagnosis*
  • Liver Cirrhosis / virology
  • Male
  • Middle Aged
  • Prospective Studies
  • ROC Curve

Substances

  • Antiviral Agents
  • Biomarkers
  • Cartilage Oligomeric Matrix Protein